Table 2 ZLDI-8 enhanced the sensitivity of HepG2 cells to Sorafenib, Etoposide or Paclitaxel

From: Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Compounds

Sorafenib

Etoposide

Paclitaxel

IC50 Value (ÎĽmol/L)

Solvent control

1.13 ± 0.05

0.34 ± 0.03

0.13 ± 0.01

ZLDI-8

0.15 ± 0.01

0.11 ± 0.01

0.02 ± 0.00

Back to article page